Research
Evidence, read off the primary source — page 2
No pattern-matched citations and no PMIDs pulled from memory. Every regulatory date, study, and label quote below was fetched live and checked against its primary source before publication — see each article's reference list. 124 articles published so far.
How we verify a source
A PubMed citation is checked against PubMed's own record, not typed from recall. A regulatory page is fetched live and quoted, not paraphrased from a secondary blog. If a claim cannot be verified this way, it is softened or removed — never guessed.
Filter by topic
Showing 25–48 of 124 articles
Evidence review
TB-500 vs. BPC-157: What the Evidence Actually Shows
One rat study put TB-500 and BPC-157 in the same experiment. Here's what it found, why it can't crown a winner, and how the two evidence bases differ.
ReadEvidence review
BPC-157, TB-500 and KPV: The FDA Compounding Decision, Explained
FDA's advisory committee reviewed seven peptides for legal compounding in July 2026. FDA staff opposed all seven. What that means for buying them now.
ReadEvidence review
Pemvidutide: What the Evidence Actually Shows
Pemvidutide is sold online as a weight-loss peptide. Its own trials show 4-6% weight loss — and a striking effect on liver fat. Live-verified status.
ReadEvidence review
CJC-1295: What the Evidence Actually Shows
CJC-1295 IS the albumin-binding DAC modification — the compound's defining feature. What its discovery paper and human trial actually show.
ReadEvidence review
Ipamorelin: What the Evidence Actually Shows
Ipamorelin has two real human trials behind it — one confirms it stimulates GH release, the other found no significant clinical benefit. Both, verified live.
ReadEvidence review
MK-677 (Ibutamoren): What the Evidence Actually Shows
MK-677 isn't a peptide — it's an oral ghrelin-receptor agonist with real 2-year trial data, a heart-failure signal, and an FDA Category 2 safety listing.
ReadEvidence review
SLU-PP-332: What the Evidence Actually Shows
SLU-PP-332 is a real synthetic ERR agonist with published mouse data across three labs — and zero human trials. Here's exactly what's been tested, and on what.
ReadEvidence review
Tesamorelin: What the Evidence Actually Shows
Tesamorelin is a real FDA-approved GHRH analog, not a gray-market peptide. What the pivotal trial, the mechanism, and the label actually show — verified live.
ReadEvidence review
5-Amino-1MQ: What the Evidence Actually Shows
5-Amino-1MQ has real mouse data behind it and zero human trials. Here's what the actual NNMT-inhibitor research shows, and what it doesn't.
ReadEvidence review
Amycretin: What the Evidence Actually Shows
Amycretin, Novo Nordisk's obesity drug, was renamed zenagamtide and is a triple agonist, not dual, live verification found. Here's the real trial data.
ReadEvidence review
AOD-9604: What the Evidence Actually Shows
AOD-9604 passed six placebo-controlled safety trials but failed its pivotal obesity trial. Here's what the evidence actually shows about it.
ReadEvidence review
Bimagrumab: What the Evidence Actually Shows
Bimagrumab is an investigational antibody, not a peptide. Real trial data shows fat loss with preserved or increased muscle, plus its Novartis-to-Lilly history.
ReadEvidence review
Cagrilintide: What the Evidence Actually Shows
In its own Phase 3 trial, cagrilintide alone underperformed semaglutide alone. Here's what the REDEFINE trial data on cagrilintide and CagriSema actually shows.
ReadEvidence review
Cerebrolysin: What the Evidence Actually Shows
Cerebrolysin has a real, substantial human trial record — mixed by indication. A 2023 Cochrane review found no mortality benefit and more non-fatal harm.
ReadEvidence review
CJC-1295 and Ipamorelin: What the Evidence Actually Shows
CJC-1295 and ipamorelin are sold as a blend, but no trial has tested them together. Here's what each compound's own evidence actually shows.
ReadEvidence review
Dihexa: What the Evidence Actually Shows
A foundational Dihexa mechanism paper was retracted for fabricated data in 2025 — verified directly against PubMed's own record, not just repeated.
ReadEvidence review
Does Insurance Cover GLP-1s? What Actually Gets Reimbursed, and What Doesn't
Medicare excluded GLP-1s for obesity until a 2026 pilot. Employer coverage varies, and compounded tirzepatide almost never bills insurance at all.
ReadEvidence review
Dulaglutide: What the Evidence Actually Shows
Dulaglutide (Trulicity) is a real, FDA-approved GLP-1 drug with its own cardiovascular indication. Here's what the head-to-head trial data actually shows.
ReadEvidence review
Exenatide: What the Evidence Actually Shows
Exenatide (Byetta) was the first FDA-approved GLP-1 drug. Here's what a live regulatory check shows about its real current marketing status and dosing history.
ReadEvidence review
Follistatin-344: What the Evidence Actually Shows
Follistatin-344's only real positive human evidence is gene therapy, not an injected protein. Injecting the protein has a published case series of eye injury.
ReadEvidence review
GHK-Cu Side Effects: What the Topical Trials Report and What Injectable Use Is Missing
GHK-Cu has real topical human trials — but zero for the injectable form. Here's what's actually been reported about safety, by route, not blended together.
ReadEvidence review
GHRP-2: What the Evidence Actually Shows
GHRP-2 is an approved diagnostic drug in Japan and a flagged FDA safety concern in the U.S. — two real, different facts. Here's what the evidence shows.
ReadEvidence review
GHRP-6: What the Evidence Actually Shows
GHRP-6 is sold as a bodybuilding GH secretagogue — but it's also the drug behind a real Cuban Phase III stroke trial. Here's what the evidence actually shows.
ReadEvidence review
GLOW Peptide Blend: What the Evidence Shows
GLOW combines GHK-Cu, BPC-157, and TB-500 in one vial. No trial has tested the combination — here's what each component's own evidence actually shows.
Read
Nothing matches these filters
No article matches both the search text and the topic selected. Try clearing one of the two filters.